What PT-141 is and what it is studied for
PT-141, also known as bremelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone that acts on melanocortin receptors in the brain — chiefly MC4R — rather than on the vascular system. Where the familiar oral compounds work on blood flow, PT-141 is studied for sexual desire and arousal at the level of the central nervous system, in both women and men.
The house window is 0.5–1.75 mg per dose, as needed, with a hard rule of no more than two doses in any seven days. There is no loading, no cycle and no maintenance; a pen is simply a number of doses. The protocol below is built around three consistent findings: the first dose should be small, the compound transiently raises blood pressure, and nausea decides most researchers' working dose.
Who it suits — and who should not run it
Written for the adult researcher — woman or man — whose desire has dropped and who has already had the obvious causes looked at: hormones, medication side effects, sleep, the relationship. It is an occasional compound for an occasional need, and it is explicitly not a performance product. The house exclusions:
Not for
- Uncontrolled or untreated high blood pressure, or any cardiovascular disease — PT-141 raises blood pressure transiently after every dose, and this is a hard exclusion.
- Pregnant, breastfeeding, or planning pregnancy in the next 6 months.
- Under 18.
- Anyone on blood-pressure medication without the prescribing physician's explicit agreement.
- A history of melanoma, or many atypical moles — melanocortin agonists act on pigment cells too.
- More than two doses a week, for anyone, for any reason.
Start gate: a resting blood pressure reading in the normal range on two separate days, and a conversation with your physician if you take anything for the heart or blood pressure.
The house protocol
Subcutaneous in the abdomen a hand's width from the navel, alternating sides, 1–2 hours before it is wanted. Not on a full stomach, and not with alcohol — both make the nausea worse. One pen = 300 clicks at 33.3 mcg per click; at the 1 mg working dose a pen is ten doses, which at the house maximum of two a week is at least five weeks.
No phases, but a fixed sequence: the first dose is always 0.5 mg, to learn how you respond to the nausea and the flush before anything else. The working dose for most researchers is 1 mg. 1.5 mg is the upper end of the house range and 1.75 mg is the soft ceiling — both are for the researcher who has tolerated 1 mg cleanly on at least two occasions, and neither is the place to start.
| Pen | Dose per injection | Clicks | Frequency | Timing | Cycle |
|---|---|---|---|---|---|
| PT-141 10 mg (33.3 mcg/click) | 0.5 mg | 15 | First dose, always | 1–2 h before, empty-ish stomach | No cycle — learn your response |
| PT-141 10 mg | 1 mg | 30 | As needed, max 2×/week | 1–2 h before | Working dose for most researchers |
| PT-141 10 mg | 1.5 mg | 45 | As needed, max 2×/week | 1–2 h before | Upper range — after two clean 1 mg doses |
| Soft ceiling | 1.75 mg (52 clicks ≈ 1.73 mg) | 52 | Never more than 2×/week | — | Never exceeded |
Dose arithmetic: a 300-click pen is 20 first-size doses, 10 working doses, or roughly 6 doses at the upper range. Keep it in the fridge between uses.
Nausea is the side effect that matters, reported by a meaningful share of researchers, usually within the first hour and usually passing within a few. Flushing and a mild headache are common; darkening at the injection site is reported with repeated use of the same spot, which is why sites rotate. Blood pressure rises transiently after a dose and settles over the following hours; a reading before the first dose and an hour after it is part of the protocol, not an optional extra. Chest discomfort or a pounding heart is a stop-and-call.
Week by week — what people typically notice and when
| When | What is typically reported |
|---|---|
| First dose (0.5 mg) | The read is tolerance: how much nausea, how much flush, how long each lasted, and the blood-pressure reading an hour in. Whether it "worked" is secondary at this dose. |
| Doses 2–3 (1 mg) | The working dose. Most researchers report the effect here, typically within 1–2 hours and lasting several. Nausea at this dose decides whether 1.5 mg is ever worth trying. |
| Doses 4+ (1–1.5 mg) | A settled dose that is used occasionally. The pattern to watch is frequency: if two a week starts to feel like not enough, the compound is being asked to do a job it is not for. |
| Any dose | Response varies, and some researchers report little at any dose. That is information, not a reason to exceed the ceiling. |
Sleep, alcohol, stress and the state of the relationship move desire more than any peptide, and the researcher who dosed PT-141 after four hours' sleep and two drinks will mostly report the nausea. Keep a short note after each dose — dose, nausea, effect, blood pressure — so the working dose is a decision made on four data points, not a guess.
Labs we ask for before and during
| Marker | When | Why it is on the list |
|---|---|---|
| Blood pressure, resting heart rate | Before the first dose · 1 h after each of the first three doses | PT-141 raises blood pressure transiently; this is the safety gate |
| Full blood count | Baseline | General safety baseline |
| Liver panel (ALT, AST, GGT, bilirubin) | Baseline | General liver check |
| Cystatin C (never creatinine alone) | Baseline | Kidney measure not distorted by muscle or creatine |
| Fasting glucose | Baseline | General metabolic baseline |
| Total and free testosterone, oestradiol, SHBG, prolactin | Baseline | Low desire is a hormone question before it is a peptide question — for women and men |
| Skin check | Baseline | A melanocortin agonist acts on pigment cells; a baseline mole map is sensible for anyone with many moles |
The hormone panel is the one that most often changes the plan: a low testosterone, a high prolactin or an oestradiol out of range explains low desire on its own, and treating that belongs with your physician before an as-needed compound is layered on top. Blood pressure around the first doses is the only "during" lab, and it is non-negotiable.
Stacking: what it pairs with
PT-141 is run on its own and is not part of any cycle. It sits alongside anything else without overlap, with two cautions: not on the same day as anything that also raises blood pressure, and not in the same evening as a DSIP dose — the timing conflicts, and the nausea window and the sleep window should not meet.
For the researcher whose low desire sits inside a bigger picture — fatigue, poor sleep, a stressful stretch — the pages to read first are NAD+, DSIP and Selank, because fixing the picture usually does more than the peptide. Alongside a fat-loss cycle on retatrutide or tirzepatide, the gut side effects of both compounds add up, and the dosing day is chosen with that in mind.
Common mistakes
- Starting at 1 mg or above. The first dose is 0.5 mg, every time, for every researcher. The nausea is not predictable from anything else.
- Skipping the blood-pressure reading. It is the one safety check the protocol has, and it takes a minute.
- A third dose in a week. Two is the ceiling. The compound is not for building a routine around.
- Dosing on a full stomach or after drinks. Both make the nausea worse and the effect less likely.
- Dosing at the moment rather than ahead of it. 1–2 hours before. At the moment is too late and the nausea arrives first.
Frequently asked questions
How many clicks is a PT-141 dose?
On the 10 mg pen, 15 clicks is 0.5 mg (the first dose, always), 30 clicks is 1 mg (the usual working dose), 45 clicks is 1.5 mg and 52 clicks is the 1.75 mg ceiling. One pen holds 300 clicks.
How often can I take PT-141?
As needed, and never more than twice in any seven days. There is no cycle and no reason to use it on a schedule.
When should I take PT-141?
1–2 hours before it is wanted, on a light stomach and without alcohol. The reported effect typically arrives within that window and lasts several hours.
Does PT-141 raise blood pressure?
Yes, transiently after each dose, which is why uncontrolled high blood pressure and cardiovascular disease are hard exclusions, and why a reading before the first dose and an hour after each of the first three doses is part of the protocol.
Does PT-141 work for women?
It is studied in both women and men, because it acts on desire and arousal centrally rather than on blood flow. The house protocol — first dose 0.5 mg, working dose 1 mg, maximum twice a week — is the same for both.
Want this written for your body, not the average one?
The personal research protocol (€399, follow-up included) takes your intake, puts it through human review, and returns a short results version plus the full clinical document — then a free coach call on WhatsApp to walk it through and read your labs against the plan.
Build my protocol Book a 15-minute call